Stent graft tested for keeping kidney and gut arteries open during aneurysm repair
NCT ID NCT05143138
First seen Sep 21, 2026 · Last updated Sep 21, 2026
Summary
Researchers are collecting real-world data on the GORE VIABAHN VBX balloon expandable endoprosthesis when doctors use it as a bridging stent with branched and fenestrated endografts to treat aortic aneurysms that involve the renal and mesenteric arteries. The registry includes adults who received this device during endovascular aneurysm repair. The main goal is to measure how many target vessels stay open without blockage or a procedure to restore flow at 12 months.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- GORE VIABAHN VBX balloon expandable endoprosthesis used as a bridging stent
- What this could lead to
- If the device performs well, doctors could have stronger evidence that this stent graft reliably keeps kidney and gut arteries open during minimally invasive aneurysm repair.
- What could go wrong
- This is a registry, not a randomized trial, so it cannot prove the device causes good outcomes. Results may not apply to all patients or centers, and the stent can still develop blockages or need repeat procedures.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
259 people
The number who actually took part.
- Started
-
Mar 2022
- Expected to finish
-
Mar 2027
An estimate. End dates often move.
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
The registry has been designed with broad eligibility criteria to capture real-world data about GORE® VIABAHN® VBX Balloon Expandable Endoprosthesis used as a Bridging Stent in conjunction with a branched/fenestrated stent graft to allow endovascular aneurysm repair. Patients will be identified from hospital database.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Patients treated with the GORE® VIABAHN® VBX Balloon Expandable Endoprosthesis as a Bridging Stent in conjunction with a branched/fenestrated stent graft to allow endovascular aneurysm repair from 31 December 2021 until 01 January 2017 2. Age ≥18 years at the time of implant 3. Provision of informed consent by the patient or next of kin/legal representative (for deceased patients at registry entry, unless a waiver was granted), according to local regulations. Exclusion Criteria: 1. Patient treated for ruptured aneurysm or who were otherwise hemodynamically unstable at the time of the procedure 2. Patient treated for acute or sub-acute dissection, \<90 days from onset of symptoms 3. Patient treated using physician-modified endovascular grafts 4. Patient intended to be treated with chimney, periscope, octopus, sandwich technique per the pre-treatment case plan 5. At the time of treatment, patient had known coagulation disorders including hypercoagulability that were not amenable to treatment 6. Patient was pregnant at the time of treatment. 7. Participation in another drug or device investigational study within one year of device implant, that can confound the registry endpoints. 8. Patient had known or suspected systemic infection (including treatment for mycotic aneurysm) at the time of implant.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Abdominal aortic aneurysm are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
"Vita-Salute" San Raffaele University I.R.C.C.S Ospedale San Raffaele
Milan, 20132, Italy
-
AMC, Meibergdreef 9
Amsterdam, 1105, Netherlands
-
Aarhus University
Aarhus, 8200, Denmark
-
Azienda Ospedaliera Complesso Ospedaliero San Giovanni Addolorata
Roma, 00184, Italy
-
Azienda Ospedaliera Universitaria Policlinico Umberto I
Roma, Italy
-
Haukeland Universitetssjukehus
Bergen, 5021, Norway
-
Hospital Clinico San Carlos
Madrid, 28040, Spain
-
Hospital Clínico Universitario San Cecilio
Granada, 18016, Spain
-
IRCCS Ospedale Policlinico San Martino
Genova, 16132, Italy
-
Rigshospitalet
Copenhagen, 2100, Denmark
-
Skane University Hospital
Malmö, 214 28, Sweden
-
St. Olavs Hospital
Trondheim, Norway
-
UNN Tromsø
Tromsø, 9038, Norway
-
Uppsala University Hospital
Uppsala, S-751 85, Sweden
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Hormone receptors in the aorta: why aneurysms hit men and women differently
- Can a nudge in your chart unlock Life-Saving genetic clues?
- Can sound waves replace CT scans for aortic aneurysm monitoring?
- Can a stent-graft keep aortic aneurysms in check for years? a long-term follow-up study aims to find out.
- Aneurysm repair may stiffen arteries — a study asks what that means for the heart
- Ultrasound reveals hidden brain risks during aortic stent surgery